Propanc Biopharma, Inc.

Latest News

Dec 4, 2025

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Joint Research Team Focusing on Impact of PRP Reversal of EMT Pathways as Central Role MELBOURNE, Australia, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the…

View All Press Releases

Dec 1, 2025

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Nov 17, 2025

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Nov 10, 2025

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline
Latest Publication Blocking Tumor Support from Cancer-Associated Fibroblasts in Tumor Microenvironment View All Publications
Trypsinogen and chymotrypsinogen: potent anti- tumor agents
Pancreatic (pro)enzymes treatment suppresses BXPC-3 pancreatic Cancer Stem Cell subpopulation and impairs tumour engrafting
Antitumour efficacy of chymotrypsinogen and trypsinogen